Medivation Slapped With Partial Hold Following PD-1 Confusion
This article was originally published in Scrip
Executive Summary
Medivation's share price dipped slightly on news that the US FDA has put a partial clinical hold on the IND for the anticancer pidilizumab (MDV9300). The decision by the regulatory agency was made after Medivation disclosed that the mechanism of action of pidilizumab was not via PD-1 inhibition, and work was "underway" to determine exactly what the mechanism is.
You may also be interested in...
With Medivation, Pfizer Sees A Chance For More Combinations
Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.